Pulse Biosciences, Inc (PLSE) – What Are Analysts Thinking About This Stock?

Pulse Biosciences, Inc (NASDAQ:PLSE) has been assigned an average recommendation of “Moderate Buy” from the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year target price among brokers that have covered the stock in the last year is $66.60.

A number of equities analysts have weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Pulse Biosciences in a research report on Thursday, October 15th. Needham & Company LLC lifted their price target on shares of Pulse Biosciences from $58.00 to $64.00 and gave the stock a “buy” rating in a report on Friday. Freedom Capital upgraded shares of Pulse Biosciences to a “strong-buy” rating in a research note on Wednesday, September 9th. Mizuho set a $65.00 price objective on shares of Pulse Biosciences in a research report on Friday. Finally, Wall Street Zen downgraded shares of Pulse Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday.

Key Headlines Impacting Pulse Biosciences

Here are the key news stories impacting Pulse Biosciences this week:

• Positive Sentiment: Six-month interim results from the PRECISE-BTN study of Pulse’s nano-pulsed field ablation treatment for thyroid nodules were described as positive. The update adds clinical evidence for the technology. Article: Pulse Biosciences’ NsPFA Treatment Shows Positive Six-Month Thyroid Study Results Article: Six-Month PRECISE-BTN Study Results
• Positive Sentiment: Canaccord Genuity raised its price target from $58 to $74 and maintained a Buy rating; Needham also reiterated Buy and raised its target from $58 to $64. These higher targets reflect improved analyst expectations. Canaccord Genuity recommendations Needham recommendations
• Positive Sentiment: The company said it completed enrollment in its U.S. pivotal IDE study in six months, three months ahead of schedule—progress toward advancing its technology. Business updates and Q3 results
• Negative Sentiment: Pulse plans a 15%–25% increase in quarterly non-GAAP expenses as it works toward a Q4 2027 CE Mark target. The added spending could weigh on cash use and future losses. Expense outlook and CE Mark target
• Negative Sentiment: Q3 revenue was $400,000, below the approximately $521,000 estimate and down 54.1% year over year. The $0.32 per-share loss was also slightly wider than the $0.31 consensus loss, underscoring the company’s limited current revenue base. Q3 results coverage

Insiders Place Their Bets

In other Pulse Biosciences news, COO Liane Teplitsky purchased 1,001 shares of Pulse Biosciences stock in a transaction on Tuesday, September 1st. The shares were acquired at an average cost of $49.95 per share, for a total transaction of $49,999.95. Following the completion of the transaction, the chief operating officer directly owned 4,095 shares of the company’s stock, valued at approximately $204,545.25. The trade was a 32.35% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Insiders purchased 4,095 shares of company stock valued at $199,931 in the last ninety days. Insiders own 74.00% of the company’s stock.

Institutional Trading of Pulse Biosciences

Several institutional investors and hedge funds have recently added to or reduced their stakes in PLSE. BlackRock Inc. bought a new stake in shares of Pulse Biosciences in the second quarter worth $40,672,000. Bank of America Corp DE purchased a new stake in shares of Pulse Biosciences in the second quarter valued at about $40,115,000. Panoramic Capital LLC bought a new stake in shares of Pulse Biosciences in the 2nd quarter worth about $2,719,000. Bank of New York Mellon Corp acquired a new position in Pulse Biosciences in the 2nd quarter valued at approximately $1,196,000. Finally, Formula Growth Ltd. acquired a new stake in shares of Pulse Biosciences in the 2nd quarter valued at $832,000. 76.95% of the stock is owned by institutional investors and hedge funds.

Pulse Biosciences Stock Performance

Shares of PLSE opened at $53.29 on Friday. Pulse Biosciences has a 12-month low of $12.56 and a 12-month high of $58.90. The stock’s 50-day moving average price is $51.55 and its 200 day moving average price is $32.28.

Pulse Biosciences (NASDAQ:PLSE) last posted its quarterly earnings data on Thursday, November 5th. The company reported ($0.32) earnings per share for the quarter, missing the consensus estimate of ($0.31) by ($0.01). Pulse Biosciences had a negative net margin of 6,755.78% and a negative return on equity of 94.42%. The company had revenue of $0.40 million for the quarter, compared to analysts’ expectations of $0.52 million. During the same quarter last year, the business posted ($0.29) EPS. The business’s quarterly revenue was down 54.1% compared to the same quarter last year. Equities analysts predict that Pulse Biosciences will post -1.34 EPS for the current year.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc (NASDAQ:PLSE) is a medical technology company developing bioelectric therapies based on its Nano-Pulse Stimulation (NPS) technology. The technology uses short, high-voltage electrical pulses to create temporary openings in cell membranes, with the goal of selectively affecting targeted cells while limiting thermal damage to surrounding tissue.

The company’s principal product is the CellFX System, a device designed to deliver NPS treatments for certain dermatologic conditions.